Drug Discovery World
MAY 30, 2024
A new research paper has validated the mechanism of action of the Atrogi’s first-in-class, small molecule, ATR-127, in combating obesity and metabolic complications. We are now advancing our next generation small molecules for the treatment of obesity to IND preparatory studies in H1 next year and expect to enter the clinic in 2026.”
Drug Target Review
JULY 4, 2023
These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. ADCs have the potential to redress the poor balance between safety and efficacy seen with traditional cancer treatment options. 3D rendering of Antibody Drug Conjugate Molecules.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
JANUARY 4, 2024
This is in part due to a complex manufacturing process, which is harder to control than those used for other modalities (such as small molecules and monoclonal antibodies). What is the unique value proposition for such approaches in the treatment of the target indications? Tell us about them.
Drug Discovery World
JANUARY 24, 2024
DDW’s Megan Thomas caught up with Wigerinck to learn more about his work with small molecules for fibrosis research. MT: Your appointment comes as Fibrocor seeks to advance two drug candidates – exquisitely specific kinase inhibitor small molecules (FIB992 and FIB991) for rare indications into the clinic.
Drug Discovery World
SEPTEMBER 6, 2022
Since 2017, a range of approvals by the FDA has resulted in cell therapies – in particular CAR-T-cell therapies – being used in the treatment of blood cancers. I would expect to see more data coming from the use of cell-based treatments for solid tumours such as breast, ovarian, pancreatic or colorectal cancer.
The Pharma Data
DECEMBER 12, 2020
AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. 5% have US Food and Drug Administration -approved treatments. 2 EvaluatePharma, World Preview 2020, Outlook to 2026.
The Pharma Data
SEPTEMBER 15, 2020
27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. The prophylactic steroid treatment was also changed from 1 mg/kg to an intermediate dose of 2mg/kg. The most frequent treatment-emergent adverse events were nasopharyngitis and atopic dermatitis.
Expert insights. Personalized for you.
147 
Let's personalize your content